Zimmer Holdings (ZMH +1%) gains today after saying that it's begun distributing its APEX Spine System, a set of implants and instruments designed to correct a broad range of spinal deformities as well as complex and degenerative spinal diseases. Under the terms of a long-term agreement with SpineCraft, Zimmer Spine will exclusively market the APEX Spine System to healthcare organizations across the U.S., Canada, Australia and New Zealand.
Zimmer Holdings (ZMH -1.9%) slips today as Credit Suisse cuts their estimates on the company's Q1 and its reiterated Neutral on the shares. The firm says that it's at the high-end of guidance range, and U.S. knee/hip market growth needs to be more carefully watched. The company lowers its 2013/2014/2015 EPS estimates to $5.74/$6.24/$6.83, from $5.76/$6.30/$6.92 respectively.
Zimmer Holdings (ZMH -1%) slips on a downgrade to Hold at Summer Street on valuation. The stock has been on a tear since the beginning of the year, rising nearly 17% on optimism over FDA clearance to market iASSIST Knee for knee replacement procedures.